• Explore /
  • Poster
  • / CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

CTC counts as a biomarker of prognosis and response in metastatic castration-resistant prostate cancer (mCRPC) from the CARD trial.

Abstract Video & Slides Poster

Authors

null

Johann S. De Bono

The Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom

Johann S. De Bono , Klaus Pantel , Eleni Efstathiou , Cora N. Sternberg , Daniel Castellano , Karim Fizazi , Bertrand Tombal , Christian Wulfing , Joseph D. Schonhoft , Audrey Gill , Lincy Chu , Rick Wenstrup , Ayse Ozatilgan , Christine Geffriaud-Ricouard , Sandrine Macé , Ronald De Wit

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Prostate Cancer - Advanced Disease

Track

Prostate Cancer - Advanced

Sub Track

Tumor Biology, Biomarkers, and Pathology

Clinical Trial Registration Number

NCT02485691

Citation

J Clin Oncol 39, 2021 (suppl 6; abstr 161)

DOI

10.1200/JCO.2021.39.6_suppl.161

Abstract #

161

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alexandra Sokolova

First Author: Howard I. Scher

First Author: Constance Thibault

First Author: Stephen J. Freedland